DENVER, March 7, 2024 -- In patients with tuberculosis (TB), a novel fixed-dose combination of alpibectir-ethionamide had similar levels of bactericidal activity as isoniazid, with no serious adverse events and good tolerability, a phase II randomized controlled trial showed.

Adding dexamethasone to treatment for tuberculous (TB) meningitis among heavily immunosuppressed HIV-positive patients in a low-resource setting did not significantly improve survival or confer any other measured benefits, a randomized controlled trial showed.